Skip to main content
Premium Trial:

Request an Annual Quote

Aventis Accepts $65.3 Billion Sanofi Takeover Bid; Deal Would Create World s 3rd Biggest Pharma

NEW YORK, April 26 (GenomeWeb News) - After having previously put up heavy resistance to a hostile takeover bid by French drug maker Sanofi-Synthelabo, Aventis said yesterday that it is recommending its shareholders accept the deal in light of improved terms.


In January, Sanofi offered roughly $60 billion to buy Aventis, which rejected the deal as offering "inferior value" to shareholders. This week, however, Aventis said that it has accepted a sweetened offer worth about $65.3 billion from Sanofi.


If accepted by Aventis' shareholders, the merger will create the world's third largest drugs firm behind number one Pfizer and number two GlaxoSmithKline - Aventis generated about $20 billion in net sales last year, while spending roughly $3.4 billion on research and development; Sanofi had sales of about $9.5 billion in 2003, and spent $1.5 billion on R&D.


The two companies also have numerous arrangements with genomics, informatics, and microarray firms, including Ardais, Affymetrix, Ingenuity, Serenex, and Pharsight. Aventis is also developing an antisense-based cancer drug with Genta.


The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.